• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


Amgen 2018 Layoffs

Quote




















































Sad to come back to CF to see amgen back at it old self. I worked for the place for over a decade and I sure don’t miss this bs. Year after year, lay off threats after lay off threats. The department I left has essentially lost all its assets in the past 5 years, at first by VTPs RIFs and then by massive attrition...so keep up the good work Amgen. Looking back all I can say is that it was a good move to move on. There is not perfect place but I can assure you there are places with less kook aid drinking even though all places have issues .

While I am here the whole idea of targets for Repatha is a joke . Get this through your thick skull amgen, the drug isn’t selling well why? Access sucks , it is a pita to write for physicians then you need to fight w insurance and then it cost too much for folks w territories outside of major metropolitan areas. That is reality but if one grows the business exponentially yet your target numbers are not where they want them to be (even though a sale is a sale) then you are in big trouble . Why is that ? In the earnings call I don’t Bradwa splitting things up between target and non target..

The lack of logic is just appalling and it just sucks to see the company I once worked for operate this way. Good luck to you all.
 




























Top Bottom
Back
Quote